4//SEC Filing
Gemphire Therapeutics Inc. 4
Accession 0001104659-16-139283
$MTVACIK 0001638287operating
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 1:27 PM ET
Size
15.8 KB
Accession
0001104659-16-139283
Insider Transaction Report
Form 4
Hawryluk P. Kent
Director
Transactions
- Conversion
Common Stock
2016-08-10$6.71/sh+23,616$158,367→ 31,889 total(indirect: By Trust) - Conversion
Common Stock
2016-08-10+7,457→ 7,457 total(indirect: By Trust) - Other
Common Stock
2016-08-10$6.71/sh+816$5,472→ 8,273 total(indirect: By Trust) - Conversion
8% Convertible Subordinated Promissory Notes
2016-08-10→ 0 total(indirect: By Trust)Exercise: $6.71→ Common Stock (23,616 underlying) - Purchase
Common Stock
2016-08-10$10.00/sh+25,000$250,000→ 56,889 total(indirect: By Trust) - Conversion
Series A Convertible Preferred Stock
2016-08-10−7,457→ 0 total(indirect: By Trust)→ Common Stock (7,457 underlying)
Holdings
- 32,062
Common Stock
Footnotes (4)
- [F1]The Series A Convertible Preferred Stock converted into shares of common stock, par value $0.001 per share (the "Common Stock"), of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering and had no expiration date.
- [F2]These shares are indirectly owned by the reporting person as trustee of the P. Kent Hawryluk Trust.
- [F3]Represents shares of Common Stock issued for payment of accrued dividends on the Series A Convertible Preferred Stock.
- [F4]The notes were issued in the original principal amount of $150,000. The outstanding principal and $8,378 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.
Documents
Issuer
Gemphire Therapeutics Inc.
CIK 0001638287
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001638287
Filing Metadata
- Form type
- 4
- Filed
- Aug 11, 8:00 PM ET
- Accepted
- Aug 12, 1:27 PM ET
- Size
- 15.8 KB